BNTX BioNTech SE American Depositary Share
XNAS
86.86
Delayed
Stock quote, options chain, IV rank, technicals, AI analysis, and institutional ownership. Iron condor setups Expected move IV rank history Fibonacci levels Insider trading
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
BNTX
$86.86
—
Key stats
$86.86
Pre-market
$87.05
+0.22%
- 52-Week Range
- $79.52 – $124.00
- YTD
- -10.17%
- IV Rank (30D)
- 47.67
- Straddle Price
- $8.10
- P/C Vol Ratio
- 3.84
- Market Cap
- $22.1B
- Open
- $86.00
- Day Range
- $85.85 – $88.87
- Volume
- 1,407,493
- Prev Close
- $88.11
Fair Value
MODEL: LONG
A blended fair-value estimate combining up to six valuation methods. Each method is weighted by how well it fits the company — DCF down-weights for unprofitable names; DDM only fires for steady dividend payers; comparables down-weight when peer multiples disagree.
- DCF (quality-aware) — projects free cash flow with a horizon that scales to business quality. True compounders (quality 6/6) get 10 years explicit + 10 years fade before terminal; cyclical/struggling names (quality 0-1) get a 5-year terminal cliff. Quality is scored from ROE, gross margin, growth, FCF margin, debt load, and FCF consistency — the same factors that drive market premium for compounders.
- Market-Implied Growth (in Model Inputs) — reverse-DCF that answers "what growth rate is the market pricing in?". Lets you sanity-check the deviation: if implied growth is plausible for the business, the model's bearish flag may be wrong; if implausible, the market may be over-extrapolating.
- DDM (Gordon Growth Dividend Model) — values the stream of future dividends. Only used when trailing yield ≥ 2% and dividend payments are stable — below that the dividend is a token payout and Gordon (which values only the dividend stream) systematically underprices growth names, so those route to DCF + comparables + market anchor instead.
- P/E, EV/EBITDA, P/B, P/S — applies the peer-group median multiple to this company's per-share metric. Peers come from the same set as the "Related symbols" card. Earnings/sales metrics are forward-tilted by the company's recent revenue growth (capped at 25%) so they're comparable to peers' growth-embedded multiples — mimics how analysts use NTM rather than TTM. Per-multiple weights are biased by company quality (e.g. P/B down-weighted for asset-light tech).
- Market Anchor (SMA50) — the 50-day moving average, weighted by recent trading-range stability (tighter Bollinger bands → higher weight). Captures information fundamentals miss (forward consensus, sentiment, supply/demand) — but only when recent trading is steady enough that the market has converged on a view. During wild breakouts or breakdowns the anchor's weight collapses.
- Options Expected (B-L 30d) — the risk-neutral expected stock price at 30-day options expiration, derived from the full implied-volatility surface via Breeden-Litzenberger (second derivative of call price wrt strike → implied PDF, then E[S_T]). Forward-looking, captures all options-implied information (smile, skew, term structure) in one number. Weighted by chain liquidity. SP500-only at present (pre-computed daily). Backtest evidence: adds modest alpha across most bucket × holding combos.
- Blended value — weighted average. Confidence reflects how many methods fired and how tight peer dispersion is.
- Deviation pill — green when blended FV ≥ 10% above current price (undervalued); red when ≥ 10% below; grey otherwise.
| 10-yr Treasury (rf) | 5.13% |
| Beta vs SPY | 0.86 |
| Cost of Equity (CAPM) | 9.43% (VRP-adj) |
| WACC | 9.46% |
| Volatility Risk Premium | +18.9pp (IV − HV30) |
| Effective Tax Rate | 21.0% |
| Rev. Growth (YoY, DCF input) | +3.0% |
| DCF Horizon | 5 years explicit + fade |
| Forward Tilt (NTM/TTM) | ×1.03 (applied to P/E, EV/EBITDA, P/S) |
| Quality Score | 0/6 — cyclical/struggling (5y DCF) |
| SMA 50 | $98.49 (Market Anchor value) |
| SMA 20 / Bollinger Mid | $93.41 |
| Bollinger Width / SMA20 | 18.0% (drives anchor stability) |
| Net Debt | $0.0B |
Peers used for multiples: AMGN, GILD, ISRG, MRNA, NTRA, REGN, TWST, VRTX
60-Day Conviction
58%
20-Day Fair Value
≈ by Nov 24, 2026
$87.57
α +0.8%
rank 49%
conviction
49%
40-Day Fair Value
≈ by Dec 23, 2026
$88.57
α +2.0%
rank 50%
conviction
63%
60-Day Fair Value
≈ by Jan 21, 2027
$88.44
α +1.8%
rank 43%
conviction
58%
| Method | Implied Price | Weight | Detail |
|---|---|---|---|
| DCF | n/a | 0% | |
| DDM (Gordon) | n/a | 0% | |
| Peer P/E | n/a | 0% | median 29.2× · 4 peers |
| Peer EV/EBITDA | n/a | 0% | median 25.2× · 5 peers |
| Peer P/B | n/a | 0% | median 14.2× · 8 peers |
| Peer P/S | n/a | 0% | median 12.2× · 8 peers |
| Market Anchor (SMA50) | $98.49 | 55% | stability 60% (BB-width) |
| Options Expected (B-L 30d) | $87.56 | 45% | 20 strikes · skew +0.14 |
As of 2026-10-26 · updated
Related
About
- Industry (SIC)
- BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) (2836) · industry map
- Exchange
- XNAS
- Market Cap
- $22.1B
- Employees
- 7,807
- List Date
- 2019-10-10
- CIK
- 0001776985
- Next Earnings
- 2026-11-03 (Pre-Market)
- EPS Forecast
- $0.85 (3 est.)
- Homepage
- https://www.biontech.de
BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including covid. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens and neoantigens; monospecific and bispecific antibodies; and antibody-drug conjugates, or ADCs. Comirnaty, its Pfizer-partnered covid vaccine, is its first commercialized product.
Summary
—
composite
—
No summary data available for this symbol yet.
Each spoke is this symbol's rank within its sector (0–100; the dotted ring marks the sector median at 50). Higher is more constructive for a long. One spoke — News sentiment — is an absolute reading, not a sector rank. Grayed spokes have no data. A fuller shape is a summary, not a recommendation.
Chart
Seasonality
| Month | '21 | '22 | '23 | '24 | '25 | '26 | Avg |
|---|---|---|---|---|---|---|---|
| Jan | 36.40% | -25.78% | -3.53% | -15.40% | 7.35% | 17.64% | 2.78% |
| Feb | -6.09% | -16.03% | -9.09% | -5.87% | -5.76% | 1.24% | -6.93% |
| Mar | -0.93% | 16.24% | -2.28% | 1.44% | -18.38% | -17.31% | -3.54% |
| Apr | 65.35% | -22.37% | -11.80% | -4.62% | 15.35% | 15.69% | 9.60% |
| May | -2.35% | 11.86% | -6.17% | 11.84% | -6.46% | -1.63% | 1.18% |
| Jun | 8.61% | -7.67% | 3.66% | -21.88% | -5.86% | 1.47% | -3.61% |
| Jul | 46.58% | 4.86% | 0.97% | 9.35% | -0.01% | -3.29% | 9.74% |
| Aug | -3.24% | -11.52% | 12.88% | 9.35% | -6.84% | 10.15% | 1.80% |
| Sep | -17.90% | -8.75% | -10.77% | 34.97% | -1.99% | -3.58% | -1.34% |
| Oct | 9.40% | 0.70% | -17.04% | -5.69% | 1.66% | -10.31%* | -3.55% |
| Nov | 28.22% | 15.92% | 7.45% | 6.20% | -0.77% | -- | 11.40% |
| Dec | -22.93% | -11.36% | 6.18% | -2.77% | -2.25% | -- | -6.63% |
| Total | 180.15% | -49.12% | -29.23% | 5.80% | -24.49% | 4.77% | 14.65% |
Technical Indicators
Quick-reference for reading the values below. Indicators combine to confirm a view — no single one is a trade signal on its own.
Trend Indicators
- SMA 20 / 50 / 200 — price above = uptrend, below = downtrend. SMA 50 crossing SMA 200 is the golden/death cross.
- EMA 12 / 26 — faster-reacting averages; 12 above 26 is short-term bullish.
- MACD — bullish when MACD > signal (green badge), bearish when below. Divergence from price often precedes reversals.
- ADX (14) — trend strength regardless of direction. <20 range, 20–25 weak trend, 25–50 trend, >50 strong trend.
- +DI / −DI — +DI > −DI favors bulls; the reverse favors bears. Read alongside ADX.
Momentum Oscillators
- RSI (14) — <30 oversold, >70 overbought. 40–60 is neutral; trending names can stay extreme.
- Stochastic %K / %D — <20 oversold, >80 overbought. %K crossing %D is an early momentum signal.
- Williams %R — inverted scale: <−80 oversold, >−20 overbought.
Oscillators work best in range-bound markets; in strong trends they give premature reversal signals.
Volume & Volatility
- Bollinger Bands — price at upper band = overbought, lower = oversold. Narrow bands (squeeze) often precede expansion.
- OBV — cumulative volume; rising OBV confirms uptrend, falling OBV confirms downtrend. Divergence from price is a warning.
- Vol SMA 20 / Vol ROC — today's volume vs. 20-day average. Positive ROC with price move = conviction.
- ATR / True Range — average daily $ move; sizing and stop-loss reference.
- HV 20 / 30 / 60 — realized (historical) volatility. Compare to IV on the options cards: IV > HV = rich premium.
Confluence matters: trend + momentum + volume agreeing carries far more weight than any single indicator. For how these feed the spread scanner score, see the algorithm docs →
Trend Indicators
SMA 20: $92.80
SMA 50: $98.36
SMA 200: $97.43
Current: $86.86
EMA 12: $90.41
EMA 26: $93.05
MACD: -2.6410 | Signal: -0.3588
BEARISH
ADX (14): 15.76
RANGE
+DI: 16.83
−DI: 31.34
Momentum Oscillators
RSI (14): 36.22
NEUTRAL
Stoch %K: 10.71
Stoch %D: 18.53
Williams %R: -92.08
Volume & Volatility
BB Upper: $100.69
BB Lower: $84.91
NEUTRAL
OBV: -27,113,228
Vol SMA 20: 1,152,094
Vol ROC: 10.21%
ATR: $3.15
True Range: $3.02
HV 20: 39.9%
HV 30: 37.8%
HV 60: 56.3%
Data Summary
Data Points: 500
Last Updated:
Date Range: 2024-10-28T00:00:00 – 2026-10-26T00:00:00
AI Analysis
LLM Stock Analysis Report
Executive Summary Overall assessment: NEUTRAL with confidence level (6/10) Key drivers: Recent news headlines, technical signals Primary risks: Moderate volatility, options market sentiment Investment thesis: BioNTech's recent CEO appointment and positive earnings sentiment may lead to short-term gains, but moderate volatility and bearish options market sentiment pose a risk. Recent news sentiment impact: The recent news headlines have been generally positive, with the CEO appointment and upcoming earnings report contributing to the neutral assessment.
Technical Analysis Trend Direction: Short-term (1-4 weeks): NEUTRAL Medium-term (1-3 months): BULLISH Long-term (3-12 months): BEARISH
Support/Resistance Levels:
- Upper band: $94.01
- Middle band: $92.06
- Lower band: $90.11
- Width: 4.23
Momentum Signals: RSI interpretation: Neutral (50.46) MACD signal: Bullish (0.14 / Signal: 0.00 / Histogram: 0.13) Bollinger Bands position: Neutral
Volume Analysis: Volume SMA 20: 898476.49 On-Balance Volume (OBV): -10777839.12 Volume Rate of Change: -87.82%
News & Sentiment Analysis Recent Headlines Summary: Positive news headlines have dominated, with the CEO appointment and upcoming earnings report contributing to the neutral assessment.
Sentiment Assessment: Neutral
Catalyst Identification:
- Upcoming earnings report on August 4, 2026
- Product launch potential
Market Narrative: The positive news headlines align with the technical signals, indicating a possible short-term gain.
Risk & Volatility Assessment Beta Interpretation: Moderate risk relative to market (beta 0.84) Volatility Regime: Current volatility is moderate compared to historical levels. Options Market Signals:
- IV rank: Low (4.5%)
- Put/call ratios: Bearish
- Unusual activity: None
Downside Protection: Support levels: $90.11, $92.06 Risk management considerations: Moderate risk, consider stop-loss levels at key support levels.
Market Context & Positioning Sector Performance: Relative strength vs sector/market: NEUTRAL
Institutional Activity: Volume patterns suggesting institutional interest: MODERATE
Correlation Analysis: How stock moves relative to market (R-squared interpretation): 0.26 - moderate correlation.
Relative Valuation: Position within trading range: NEAR THE LOWER END OF THE RANGE.
Key Levels & Action Items Critical Price Levels:
- Support/resistance at $92.06, $94.01
- Breakout/breakdown levels: $90.11 (key support)
Time-Sensitive Catalysts:
- Earnings report on August 4, 2026
- Product launch potential
Risk Management: Stop-loss levels: Consider placing stop-loss orders at key support levels. Position sizing considerations: Moderate risk, consider reducing position size to manage risk.
Note: This analysis is based on the provided data and should not be considered as a buy or sell recommendation. The report highlights both bullish and bearish cases, with a neutral assessment based on recent news headlines and technical signals.
Generated
News
All BNTX news →
It has been a volatile year for the biotech.
BioNTech has billions in cash, and its oncology programs are moving into late-stage clinical trials.
Showing 1–10 of 19
Page 1 of 2
BNTX Options Activity & IV Rank
BNTX IV rank history, 52-week IV rank and IV percentile →
Volatility Metrics
Current IV: 45.3%
7-DTE IV: —
Expected Move: $8.10
7-DTE Move: $8.10
Days to Exp: 25 (2026-11-20)
Options Flow
Call Volume: 171
Put Volume: 657
P/C Volume: 3.842
BEARISH
Call OI: 3,732
Put OI: 2,139
P/C OI: 0.573
Total OI: 5,871
ATM Options Pricing
ATM Call: $4.12
ATM Put: $3.98
Call %: 4.7%
Put %: 4.6%
Chain Summary
Chain Volume: 5,078
Chain OI: 46,969
Last Updated: 10/26/2026
Spread Scanner GPU
Each spread is ranked by a composite score built in three stages. Full documentation →
Stage 1 — Base Score (GPU scanner)
score = P(profit) × (credit / spread_width)
P(profit) from short leg delta (1 − |delta|), penalised above 85%. Credit uses mid-price to handle illiquid chains fairly.
Stage 2 — Skew Adjustment (±25% cap)
RR and BF (30-delta) from the persisted per-symbol skew snapshot — wing strikes picked by real greeks.delta, not a moneyness proxy. Put skew boosts bull puts, penalises bear calls. High butterfly boosts iron condors. Calendars are skew-neutral.
Stage 3 — Technical Overlay (±50% cap, 5 groups)
Group 1 · Directional Bias (±0.25)
- RSI <40 bullish / >60 bearish
- MACD crossover + histogram trend
- Price vs SMA 50 & SMA 200
Group 2 · Momentum (±0.10)
- Stochastic %K <20 / >80
- Williams %R <−80 / >−20
Group 3 · Volatility (up to −0.25 / +0.15)
- Blended ATR + straddle expected-move penalty
- Bollinger Band signal (+ counter-trend penalty)
- BB width — vol contraction boost for ICs
Group 4 · IV Regime (±0.15)
- IV rank ≥ 75 → strong boost for credit spreads
- IV rank < 25 → penalty (selling cheap vol)
Group 5 · Liquidity (penalty up to −0.10)
- Min open interest across all legs
- OI < 100 → −0.10 · OI < 500 → −0.05
score = base_score × skew_multiplier × tech_multiplier
Both multipliers are shown per spread. Beta is informational only — ATR already captures realized vol. Full algorithm documentation →
Enter a ticker to scan for optimal spread opportunities.
Evaluates all bull put, bear call, iron condor, and calendar spread combinations using GPU-accelerated analysis.
Dealer Positioning
LOW γ vs HISTORY
Estimated net dealer gamma is at the 13th percentile of this name's own daily history, near the low end of its range. This describes current positioning; it is not a forecast or a trading signal.
Gamma percentile
13%
vs own history
GEX tilt
-0.61
OI-weighted, today
Vanna tilt
-0.05
δ-sensitivity to IV
Charm tilt
+0.17
δ-decay vs time
? What is this?
· 55 ATM contracts, 10k total OI
Net dealer gamma is an estimate of the aggregate gamma held by options market makers across this name's option chain, weighted by open interest. Dealer positions aren't public, so it uses a standard simplifying assumption: dealers are treated as long the calls and short the puts that are open. Actual dealer books can differ.
Gamma percentile ranks today's estimate against this name's own daily history, from 0% (the lowest reading on record) to 100% (the highest). Raw gamma scales with how much open interest a chain carries, so it isn't comparable across names; the percentile is. The badge marks the bottom 20% as low and the top 20% as high.
Tilts run from −1 to +1 and show how lopsided the estimated dealer exposure is. GEX tilt compares call gamma with put gamma. Vanna tilt describes how the hedge would shift if implied volatility changed, and charm tilt how it would shift with the passage of time.
This card describes estimated positioning and where it sits historically. It is not a forecast of price direction or volatility and not a trading signal. Market-wide view: Dealer positioning screener.
Skew (Wing IV − ATM IV)
DTE:
Wing Δ:
Wing vs ATM
IV(put wing) − IV(ATM), in vol pointsHow much the OTM put trades above (or below) the at-the-money strike. Measures the height of the put-side tail relative to ATM — i.e. how expensive crash insurance is on this name.
- Positive (typical) — wing IV > ATM IV. Standard equity put skew: portfolios bid up crash protection, so OTM puts trade richer than ATM.
- Near zero or negative (unusual) — wing IV ≤ ATM IV. Flat or inverted put side. Common when there's no fear demand, in tightly mean-reverting names, or right after an earnings catalyst clears.
- Percentile vs own 3-yr history: high = wings rich (good time to sell wing premium); low = wings cheap (good time to buy protection).
- Not directional — high or low wings don't predict up or down moves. It's a price tag on tail insurance, not a forecast.
Risk Reversal
IV(call wing) − IV(put wing), equal delta on each sideWhich side of the smile is the market paying up for? Measures the tilt of the surface — call skew vs put skew at matched deltas.
- Negative (typical) — puts richer than calls. Standard equity behavior: hedging demand makes puts carry a premium. Most large-caps sit in the −1 to −5 vol-point range.
- Strongly negative (< −5 pts) — heavy downside hedging, elevated fear, or an upcoming catalyst (earnings, FDA, macro event). Worth flagging.
- Positive — calls richer than puts. Unusual for equities; signals bullish momentum, short-squeeze positioning, or takeover/M&A speculation.
- Near zero — symmetric surface. Market sees roughly equal up/down risk. Rare for large-caps; more common in commodities and FX.
Reading them together
Wing-vs-ATM tells you how expensive the tails are. Risk Reversal tells you which side is favored. Combined:
- High wing percentile + deeply negative RR → strong put bid; stress or major event priced in. Owning protection costs a premium; selling put premium is dangerous.
- Low wing percentile + near-zero RR → complacency; insurance cheap and balanced. Good environment to add cheap downside hedges.
- Positive RR + elevated wings → call-side fear-of-missing-out; common in squeeze setups. Upside calls expensive, downside puts not bid.
14 DTE / 10d
—
—
pts
EXTREME
as of Oct 26 · No data
30 DTE / 10d
83%
+8.7
pts
EXTREME
as of Oct 26 · ATM 44.2% / Wing 52.9%
Extreme reading.
Historically these have been contrarian — on the small set of observed earnings-day cases, large negative wing-vs-ATM gaps (calls pricing much richer than puts at the same delta) preceded sharp drops in the underlying within 1-12 days. Not financial advice and the dataset is small.
Percentile is the rank of today's reading within ~3 years of this symbol's own history. High percentile = wings are rich relative to history; not a directional signal. Skew is read off the chain in real time, not from CBOE SKEW.
Volatility Surface
Enter a ticker to render the implied volatility surface.
Volatility Smile
Enter a ticker to render the implied volatility smile.
IV Rank (7 DTE)
IV Rank (30 DTE)47.7MediumOct 26
Straddle Price (30 DTE)$8.10Oct 26
Beta Analysis
Risk Metrics
Beta: 0.9600
Alpha: -21.38%
Correlation: 0.2609
R-Squared: 6.8%
Stock Volatility: 46.9%
Market Volatility: 12.7%
Analysis Details
Benchmark: SPY
Data Points: 251
Period: 252 trading days
Data Points: 251
Period: 252 trading days
Interpretation:
Moderate volatility - stock generally follows market
Moderate volatility - stock generally follows market
Beta & Alpha Over Time
Notable investors who own BNTX
3 of 37 tracked investors
| Investor | Value | Share of their portfolio | Rank | Q/Q shares | Source |
|---|---|---|---|---|---|
| Citadel Hedge fund Ken Griffin | $33.9M | #872 of 6285 | -61.7% | 13F | |
| Point72 Hedge fund Steve Cohen | $30.4M | #464 of 1945 | new | 13F | |
| Rockefeller Capital Management Family office Rockefeller family | $184K | #2641 of 4729 | -0.8% | 13F |
Hedge funds, activists, holding companies and family offices we track, from their latest 13F (quarter-end value) and Form 4 filings in the last 3 years. Family offices · all institutions
BNTX Institutional Ownership (13F)
Latest filings — 2026-09-30Institutional managers with $100M+ AUM file Form 13F-HR quarterly, due 45 days after quarter end. Holdings are reported gross at quarter-end market value — they are a snapshot, not a real-time position.
- Shares — long equity positions in this name, aggregated across share classes.
- Calls / Puts — notional value of long call / put exposure where this ticker is the underlying.
- % of Float — holder's reported shares divided by the latest diluted shares outstanding. Sums above 100% indicate large custodian / prime broker positions where the same shares are reported by multiple filers.
- Custodian badge — filers with more than 5,000 holdings are typically broker-dealers / custodians reporting customer-held shares, not active managers.
Each filer is counted once at its latest 13F-HR filing. New filings are ingested on a weekly cadence.
24 filers$122.30M notional
| # | Filer | Notional Value | % of Total | Period |
|---|---|---|---|---|
| 1 | Squarepoint Ops LLC | $29.97M | 24.51% | 2026-06-30 |
| 2 | Citadel Advisors LLC Custodian | $17.69M | 14.46% | 2026-06-30 |
| 3 | Susquehanna International Group, LLP Custodian | $14.54M | 11.89% | 2026-06-30 |
| 4 | IMC-Chicago, LLC Custodian | $12.51M | 10.23% | 2026-06-30 |
| 5 | DIADEMA PARTNERS LP | $9.30M | 7.61% | 2026-06-30 |
| 6 | Walleye Trading LLC | $7.39M | 6.04% | 2026-06-30 |
| 7 | Jane Street Group, LLC Custodian | $4.89M | 3.99% | 2026-06-30 |
| 8 | Wolverine Trading, LLC Custodian | $4.55M | 3.72% | 2025-09-30 |
| 9 | Citigroup Inc. Custodian | $3.49M | 2.85% | 2026-06-30 |
| 10 | Simplex Trading, LLC Custodian | $3.41M | 2.79% | 2026-06-30 |
| 11 | GROUP ONE TRADING LLC Custodian | $3.27M | 2.67% | 2026-06-30 |
| 12 | Vontobel Holding Ltd. | $2.75M | 2.25% | 2026-09-30 |
| 13 | JPMorgan Chase & Co Custodian | $1.89M | 1.54% | 2026-06-30 |
| 14 | Caption Management, LLC | $1.86M | 1.52% | 2026-06-30 |
| 15 | Walleye Capital LLC | $1.66M | 1.35% | 2026-06-30 |
| 16 | TUDOR INVESTMENT CORP ET AL | $1.24M | 1.01% | 2026-06-30 |
| 17 | Twin Tree Management, LP | $651.35K | 0.53% | 2026-06-30 |
| 18 | Balyasny Asset Management L.P. | $474.56K | 0.39% | 2026-06-30 |
| 19 | Millennium Management LLC Custodian | $279.15K | 0.23% | 2026-06-30 |
| 20 | Two Sigma Investments, LP Custodian | $204.71K | 0.17% | 2026-06-30 |
| 21 | SG Americas Securities, LLC | $116.00K | 0.09% | 2026-06-30 |
| 22 | Persistent Asset Partners Ltd | $110.63K | 0.09% | 2026-06-30 |
| 23 | UBS Group AG Custodian | $46.52K | 0.04% | 2026-06-30 |
| 24 | PEAK6 LLC | $9.30K | <0.01% | 2026-06-30 |
23 filers$169.42M notional
| # | Filer | Notional Value | % of Total | Period |
|---|---|---|---|---|
| 1 | Citadel Advisors LLC Custodian | $35.78M | 21.12% | 2026-06-30 |
| 2 | Susquehanna International Group, LLP Custodian | $30.78M | 18.17% | 2026-06-30 |
| 3 | Squarepoint Ops LLC | $27.75M | 16.38% | 2026-06-30 |
| 4 | Walleye Trading LLC | $15.77M | 9.31% | 2026-06-30 |
| 5 | IMC-Chicago, LLC Custodian | $11.70M | 6.90% | 2026-06-30 |
| 6 | Jane Street Group, LLC Custodian | $9.97M | 5.88% | 2026-06-30 |
| 7 | Citigroup Inc. Custodian | $8.14M | 4.81% | 2026-06-30 |
| 8 | D. E. Shaw & Co., Inc. Custodian | $6.05M | 3.57% | 2026-06-30 |
| 9 | Simplex Trading, LLC Custodian | $4.66M | 2.75% | 2026-06-30 |
| 10 | GROUP ONE TRADING LLC Custodian | $3.12M | 1.84% | 2026-06-30 |
| 11 | TUDOR INVESTMENT CORP ET AL | $2.88M | 1.70% | 2026-06-30 |
| 12 | Wolverine Trading, LLC Custodian | $2.46M | 1.45% | 2025-09-30 |
| 13 | JPMorgan Chase & Co Custodian | $1.89M | 1.11% | 2026-06-30 |
| 14 | Twin Tree Management, LP | $1.81M | 1.07% | 2026-06-30 |
| 15 | Goldman Sachs Group Inc Custodian | $1.16M | 0.69% | 2026-06-30 |
| 16 | Balyasny Asset Management L.P. | $1.16M | 0.69% | 2026-06-30 |
| 17 | Walleye Capital LLC | $902.59K | 0.53% | 2026-06-30 |
| 18 | Verition Fund Management LLC | $837.45K | 0.49% | 2026-06-30 |
| 19 | UBS Group AG Custodian | $780.69K | 0.46% | 2026-06-30 |
| 20 | Millennium Management LLC Custodian | $623.43K | 0.37% | 2026-06-30 |
| 21 | PEAK6 LLC | $558.30K | 0.33% | 2026-06-30 |
| 22 | Vontobel Holding Ltd. | $481.67K | 0.28% | 2026-09-30 |
| 23 | HAP TRADING, LLC | $175.50K | 0.10% | 2025-09-30 |
BNTX Insider Trading (Form 4)
Latest: 2026-10-09Form 4 filings — insider beneficial-ownership changes by officers, directors, and 10%+ holders. Filed within 2 business days of transaction.
| Filed | Reporter | Role | Action | Shares | Avg Price | Net $ | Link |
|---|---|---|---|---|---|---|---|
| 2026-10-09 | Ugur Sahin | Chief Executive Officer | Sell (S) | −63,209 | $94.07 | -$5.95M | EDGAR |
| 2026-10-07 | Ugur Sahin | Chief Executive Officer | Sell (S) | −24,000 | $95.86 | -$2.30M | EDGAR |
| 2026-10-06 | Ugur Sahin | Chief Executive Officer | Sell (S) | −93,000 | $97.14 | -$9.03M | EDGAR |
| 2026-10-02 | Ugur Sahin | Chief Executive Officer | Sell (S) | −34,000 | $97.09 | -$3.30M | EDGAR |
| 2026-09-30 | Ugur Sahin | Chief Executive Officer | Sell (S) | −66,000 | $98.19 | -$6.48M | EDGAR |
| 2026-09-28 | Ugur Sahin | Chief Executive Officer | Sell (S) | −61,000 | $98.57 | -$6.01M | EDGAR |
| 2026-09-24 | Ugur Sahin | Chief Executive Officer | Sell (S) | −69,000 | $99.17 | -$6.84M | EDGAR |
| 2026-09-22 | Ugur Sahin | Chief Executive Officer | Sell (S) | −79,000 | $99.50 | -$7.86M | EDGAR |
| 2026-09-18 | Ugur Sahin | Chief Executive Officer | Sell (S) | −64,000 | $97.49 | -$6.24M | EDGAR |
| 2026-09-16 | Ugur Sahin | Chief Executive Officer | Sell (S) | −49,000 | $96.37 | -$4.72M | EDGAR |
| 2026-09-14 | Ugur Sahin | Chief Executive Officer | Sell (S) | −86,000 | $98.13 | -$8.44M | EDGAR |
| 2026-09-11 | Ugur Sahin | Chief Executive Officer | Sell (S) | −20,500 | $96.31 | -$1.97M | EDGAR |
| 2026-09-09 | Ugur Sahin | Chief Executive Officer | Sell (S) | −73,000 | $98.50 | -$7.19M | EDGAR |
| 2026-09-08 | Ugur Sahin | Chief Executive Officer | Sell (S) | −76,500 | $103.12 | -$7.89M | EDGAR |
| 2026-05-13 | James Timothy Patrick Ryan | See remarks. | Grant (A) | +22,655 opt | — | EDGAR |
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (described in filing footnote — typically 401(k), trust, inheritance) · W = will/inheritance. Only P / S codes carry directional signal.
BNTX Insider Holdings
2 insiders · @ $86.86
Officers, directors, and 10%+ owners who have filed a Form 4 in the past two years, ranked by current disclosed exposure (shares × today's price). Shares are direct + indirect (via trusts / LLCs / spouse). Excludes unvested RSU and option grants — those aren't beneficially owned until vest.
| # | Insider | Role | Shares | Disclosed Exposure | Lifetime OM Net | Filings | Last Filed |
|---|---|---|---|---|---|---|---|
| 1 | Ugur Sahin | Chief Executive Officer | 39,218,111 | $3.41B | -$84.23M | 14 | 2026-10-09 |
| 2 | Sierk Poetting | Chief Operating Officer | 399,387 | $34.69M | -$5.53M | 2 | 2026-05-13 |
Lifetime OM Net = signed sum of open-market buys (P) and sells (S) over their career; excludes grants, tax withholdings, and dispositions to issuer. A large negative number is normal for long-tenured executives — they've sold compensation grants over many years.
ETF Holders
31 ETFs hold BNTX
25 shown · $228.85M total exposure · 0.22% AUM-weighted avg weight
| # | ETF | Provider | Weight | $ Exposure | ETF AUM | As Of |
|---|---|---|---|---|---|---|
| 1 | FBT First Trust NYSE® Arca® Biotechnology Index Fund | First Trust | 2.99% | $89.0M | $3.0B | 2026-10-23 |
| 2 | IBB iShares Biotechnology ETF | iShares (BlackRock) | 0.60% | $64.2M | $10.7B | 2026-10-23 |
| 3 | FNDF Schwab Fundamental International Equity ETF | Nport | 0.08% | $18.9M | — | 2026-05-31 |
| 4 | IDNA iShares Genomics Immunology and Healthcare ETF | iShares (BlackRock) | 2.88% | $9.2M | $321.2M | 2026-10-23 |
| 5 | SPDW State Street® SPDR® Portfolio Developed World ex-US ETF | SPDR (State Street) | 0.02% | $8.8M | $40.7B | 2026-10-23 |
| 6 | BBH VanEck Biotech ETF | VanEck | 1.41% | $7.1M | $503.3M | 2026-10-23 |
| 7 | BBEU JPMorgan BetaBuilders Europe ETF | JPMorgan | 0.07% | $6.4M | $8.9B | 2026-10-26 |
| 8 | QQQJ Invesco NASDAQ Next Gen 100 ETF | Invesco | 0.52% | $6.1M | — | 2026-10-24 |
| 9 | BBIN JPMorgan BetaBuilders International Equity ETF | JPMorgan | 0.04% | $2.9M | $6.5B | 2026-10-26 |
| 10 | ONEQ Fidelity Nasdaq Composite Index ETF | Fidelity | 0.02% | $2.5M | $10.7B | 2026-10-23 |
| 11 | GNOM Global X Genomics & Biotechnology ETF | Global X | 2.30% | $2.4M | — | 2026-10-26 |
| 12 | KOMP State Street® SPDR® S&P Kensho New Economies Composite ETF | SPDR (State Street) | 0.09% | $2.3M | $2.5B | 2026-10-23 |
| 13 | PXF Invesco RAFI Developed Markets ex-U.S. ETF | Nport | 0.07% | $1.9M | — | 2026-07-31 |
| 14 | XT iShares Future Exponential Technologies ETF | iShares (BlackRock) | 0.05% | $1.8M | $4.0B | 2026-10-23 |
| 15 | BBP Virtus Biotech Etf | Nport | 1.38% | $1.4M | — | 2026-07-31 |
| 16 | IBBQ Invesco Nasdaq Biotechnology ETF | Invesco | 0.68% | $784,224 | — | 2026-10-24 |
| 17 | NXTE AXS Green Alpha ETF | Nport | 1.19% | $683,266 | — | 2026-06-30 |
| 18 | BKIE BNY Mellon International Equity ETF | Nport | 0.04% | $486,042 | — | 2026-07-31 |
| 19 | GINN Goldman Sachs Innovate Equity ETF | Goldman | 0.24% | $422,688 | $176.4M | 2026-10-23 |
| 20 | BIB ProShares Ultra NASDAQ Biotechnology | ProShares | 0.42% | $401,641 | — | 2026-10-26 |
| 21 | HELX Franklin Genomic Advancements ETF | Franklin | 1.05% | $363,770 | $34.7M | 2026-10-26 |
| 22 | APIE ActivePassive International Equity ETF | Nport | 0.03% | $304,424 | — | 2026-08-31 |
| 23 | TMED T. Rowe Price Health Care ETF | Nport | 1.29% | $296,643 | — | 2026-06-30 |
| 24 | BGIA Baillie Gifford International Alpha ETF | Nport | 0.28% | $186,844 | — | 2026-06-30 |
| 25 | IQSI NYLIM Candriam International Equity ETF | Nport | 0.07% | $179,719 | — | 2026-07-31 |
Fundamentals
Quarterly filings sourced from SEC 10-Q / 10-K reports. TTM tiles aggregate the most recent four quarters; bars show the last ~12 quarters oldest → newest.
Metrics
- Revenue — top-line sales. Look for consistent YoY growth; seasonal businesses need same-quarter comparisons (Q4 '24 vs Q4 '23).
- Net Income — bottom-line profit after all expenses. Can be volatile from one-time items; red bars = net loss.
- Diluted EPS — net income per share assuming options/converts are exercised. Direct input to the P/E ratio.
- Operating Cash Flow — cash generated from core operations, before capex and financing. Harder to manipulate than net income; growing OCF is a quality signal.
How to read the bars
- Sequential growth — quarter-over-quarter trend. Accelerating bars are a momentum signal.
- YoY growth — compare to the same quarter a year earlier to remove seasonality.
- Quality — OCF should roughly track Net Income over time. Large divergence (net income ≫ OCF) flags accruals risk.
- Margins — scan the bar ratios: Net Income / Revenue tells you margin trend without needing a separate chart.
TTM (trailing-twelve-month) smooths seasonality and is used for the P/E calculation. Filings appear 30–90 days after the period closes.
Trailing P/E
—
TTM Diluted EPS
—
TTM Revenue
—
TTM Net Income
—
TTM Op. Cash Flow
—
Short Interest & Float
Regulatory short-interest reports publish on a bi-weekly settlement cadence; short-volume is reported daily by the trade-reporting facilities. Float is derived from insider-ownership filings.
Metric definitions
- Short Interest — total shares currently sold short as of the settlement date. Lags real time by ~8 business days.
- SI % of Float — short interest / free float. The key crowding metric.
- Days to Cover — short interest / avg daily volume. How many full trading days it would take shorts to buy back. High DTC + catalyst = squeeze fuel.
- Short Vol Ratio — today's short-sale volume / total volume. Intraday selling pressure proxy (not the same as short interest).
- Free Float — shares available for public trading (total shares minus insider / restricted).
- Float % — free float / shares outstanding. <50% = tightly held, more prone to squeezes.
How to read the signals
- SI % of Float < 5% — typical, no particular signal.
- 5–15% — elevated; watch for catalysts (earnings, guidance, macro).
- 15–30% — heavily shorted; tight-float names in this range have produced notable squeezes historically.
- >30% — extreme; borrow is likely expensive and squeeze risk is material.
- Days to Cover > 5 combined with high SI% amplifies squeeze potential.
History chart
- Trend matters more than level. Rapidly rising short interest often precedes negative catalysts or heavy hedging.
- A sudden drop in SI after a rally may indicate a squeeze in progress.
Short interest is reported mid-month and end-of-month; short volume is daily.
Short Interest
2.50M
SI % of Float
0.99%
Days to Cover
3.12
Short Vol Ratio
26.2%
Free Float
—
Float %
—
Short interest 2026-09-30 • Short volume 2026-10-26